{"entity":{"id":"nct07265622","kind":"trial","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of 7MW4911 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07265622 by Mabwell (Shanghai) Bioscience Co., Ltd., with 200 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-07. Interventions recorded: 7MW4911.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07265622","url":"https://clinicaltrials.gov/study/NCT07265622"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07265622","phase":"1/2","setting":"A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of 7MW4911 in Patients With Advanced Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":200,"outcomes":[]},"route":"/trials/nct07265622/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}